Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

343 ARTÍCULOS , VIENDO DEL 301 AL 315

How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?

Gauthier S, Leuzy A, Rosa-Neto P.

Neurodegener Dis. 2014;13(2-3):197-9. doi: 10.1159/000353748. Epub 2013 Aug 7.

Tau immunotherapy and imaging

Sigurdsson EM.

Neurodegener Dis. 2014;13(2-3):103-6. doi: 10.1159/000354491. Epub 2013 Sep 11.

Intervention strategies for spatial orientation disorders in dementia: a selective review

Caffò AO, Hoogeveen F, Groenendaal M, Perilli AV, Picucci L, Lancioni GE, Bosco A.

Dev Neurorehabil. 2014 Jun;17(3):200-9. doi: 10.3109/17518423.2012.749951. Epub 2013 Oct 8.

The therapeutic effects of human adipose-derived stem cells in Alzheimer's disease mouse models

Chang KA, Kim HJ, Joo Y, Ha S, Suh YH.

Neurodegener Dis. 2014;13(2-3):99-102. doi: 10.1159/000355261. Epub 2013 Oct 23.

Cost analysis of early psychosocial intervention in Alzheimer's disease

Søgaard R, Sørensen J, Waldorff FB, Eckermann A, Buss DV, Waldemar G.

Dement Geriatr Cogn Disord. 2014;37(3-4):141-53. doi: 10.1159/000355368. Epub 2013 Oct 19.

Effect of donepezil in Alzheimer disease can be measured by a computerized human analog of the Morris water maze

Hort J, Andel R, Mokrisova I, Gazova I, Amlerova J, Valis M, Coulson EJ, Harrison J, Windisch M, Laczó J.

Neurodegener Dis. 2014;13(2-3):192-6. doi: 10.1159/000355517. Epub 2013 Oct 30.

Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult

Rosenblum WI.

Neurobiol Aging. 2014 May;35(5):969-74. doi: 10.1016/j.neurobiolaging.2013.10.085. Epub 2013 Oct 19.

Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets

Barone E, Di Domenico F, Butterfield DA.

Biochem Pharmacol. 2014 Apr 15;88(4):605-16. doi: 10.1016/j.bcp.2013.10.030. Epub 2013 Nov 11.

Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease

Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, Jacobsen J.

Dement Geriatr Cogn Disord. 2014;37(3-4):232-45. doi: 10.1159/000355373. Epub 2013 Nov 14.

Regenerative medicine in Alzheimer's disease

Felsenstein KM, Candelario KM, Steindler DA, Borchelt DR.

Transl Res. 2014 Apr;163(4):432-8. doi: 10.1016/j.trsl.2013.11.001. Epub 2013 Nov 8.

[Does gender really affect the socio-economic characteristics of the primary caregiver in Alzheimer's disease?]

Ruiz-Adame Reina M, González-Camacho MC, Mainar Causapé A.

Gac Sanit. 2014 May-Jun;28(3):258. doi: 10.1016/j.gaceta.2013.09.004. Epub 2013 Dec 2.

Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches

Mikulca JA, Nguyen V, Gajdosik DA, Teklu SG, Giunta EA, Lessa EA, Tran CH, Terak EC, Raffa RB.

J Clin Pharm Ther. 2014 Feb;39(1):25-37. doi: 10.1111/jcpt.12112. Epub 2013 Dec 8.

Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures

Chakroborty S, Stutzmann GE.

Eur J Pharmacol. 2014 Sep 15;739:83-95. doi: 10.1016/j.ejphar.2013.11.012. Epub 2013 Dec 6.

A small molecule that displays marked reactivity toward copper- versus zinc-amyloid-β implicated in Alzheimer's disease

Savelieff MG, Liu Y, Senthamarai RR, Korshavn KJ, Lee HJ, Ramamoorthy A, Lim MH.

Chem Commun (Camb). 2014 May 25;50(40):5301-3. doi: 10.1039/c3cc48473d. Epub 2013 Dec 10.

Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease

El-Malah A, Gedawy EM, Kassab AE, Salam RM.

Arch Pharm (Weinheim). 2014 Feb;347(2):96-103. doi: 10.1002/ardp.201300121. Epub 2013 Dec 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias